Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Pharmacoeconomics|June 7, 1992
Assessing the responsiveness of a quality-of-life instrument and the measurement of symptom severity in essential hypertensionM C Reilly, A S ZbrozekNursing Economic$|July 1, 1994
Mannitol injections: with or without filter needles? A cost-effectiveness analysisA S Zbrozek, E Agbara, M HeadDrug Intelligence & Clinical Pharmacy|November 1, 1988
Compatibility and stability of cefazolin sodium, clindamycin phosphate, and gentamicin sulfate in two intravenous solutionsA S Zbrozek, D A Marble, J A BossoPharmacoeconomics|October 5, 1993
The validity and reproducibility of a work productivity and activity impairment instrumentM C Reilly, A S Zbrozek, E M DukesAmerican Journal of Hospital Pharmacy|June 15, 1994
Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomitingA S Zbrozek, S B Cantor, M P Cardenas, et al.Drug Intelligence & Clinical Pharmacy|October 1, 1987
Compatibility and stability of clindamycin phosphate-aminoglycoside combinations within polypropylene syringesA S Zbrozek, D A Marble, J A Bosso, et al.Journal of the American Geriatrics Society|June 16, 2000
Predicting 10-year care requirements for older people with suspected Alzheimer's diseaseB P Kinosian, E Stallard, J H Lee, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|November 1, 2011
Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimensR Gniadecki, D Robertson, C T Molta, et al.The American Journal of Cardiology|September 1, 1993
Effectiveness and costs of digoxin treatment for atrial fibrillation and flutterS A Roberts, C Diaz, P E Nolan, et al.Diabetes Care|May 1, 1997
Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemiaR C Eastman, J C Javitt, W H Herman, et al.Pageof 2